Drug Trial Radar · NCT07932990
Halova Vaginal Ovules Versus Vaginal Estriol for Genitourinary Symptoms in Postmenopausal Women
Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
252
Actual
Start
Mar 7, 2025
Primary completion
Apr 22, 2026
Study completion Jun 22, 2026
Sponsor
- Lead sponsor
- Perfect Care DistributionIndustry
- Sponsor type
- Industry
- First posted
- Nov 12, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical study was to compare Halova vaginal ovules, a non-hormonal medical device, with vaginal estriol 0.5 mg, an estrogen treatment, for genitourinary symptoms in postmenopausal women. The main questions were: * How do the treatments compare in reducing bothersome symptoms and improving vaginal health? * How do the treatments affect sexual function? * What medical problems and changes in the thickness of the lining of the uterus occur during the study? * Are improvements maintained after treatment has ended? Women willing to receive either treatment were randomly assigned to Halova or estriol in a 1:1 ratio. Women who declined hormonal therapy received Halova without randomization. Participants knew which treatment they received, while the clinicians assessing clinical outcomes did not know their treatment assignment. Participants: * Used one vaginal ovule daily for the first two weeks, then one ovule twice weekly until the end of the 12-week treatment period. * Attended assessments at baseline, Week 12, and Week 24 for symptoms, vaginal health, sexual function, safety, and the thickness of the lining of the uterus. * Received telephone monitoring at Weeks 2, 4, and 8 for treatment use, tolerability, medical problems, and satisfaction. * Received individualized menopause-related education and written materials, and completed a questionnaire about knowledge, attitudes, and behaviors at baseline and Week 12.
Conditions
- Genitourinary Syndrome of Menopause (GSM)
- Vaginal Dryness
- Vulvo Vaginal Atrophy (VVA)
Interventions
Halova vaginal ovulesDevice
Halova is a vaginal medical device formulated as ovules containing sodium hyaluronate (5 mg per ovule) and xylitol (3 mg per ovule), together with semi-synthetic glycerides, lanolin, Aloe vera oil extract, Calendula officinalis extract, colloidal silicon dioxide, and vitamin E. One ovule was administered intravaginally daily for the first two weeks, followed by one ovule twice weekly until the end of the 12-week treatment period.
Estriol 0.5 mg vaginal ovulesDrug
Each Ovestin vaginal ovule contained estriol 0.5 mg. One ovule was administered intravaginally daily for the first two weeks, followed by one ovule twice weekly until the end of the 12-week treatment period.
Menopause-related education and counselingBehavioral
All participants received individualized counseling and written educational materials about menopause, genitourinary symptoms, and available management options. A study-specific questionnaire was administered before the educational intervention at baseline and again at Week 12. This intervention was common to all three allocation arms.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Most Bothersome Symptom (MBS) Score at Week 12Time frame: Baseline and Week 12
- Change From Baseline in Study-Adapted Vaginal Health Index (VHI) Total Score at Week 12Time frame: Baseline and Week 12
- Change From Baseline in Vaginal pH Component Score of the Study-Adapted VHI at Week 12Time frame: Baseline and Week 12
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Arad County Clinical Emergency Hospital - Department of Obstetrics and Gynecology
Arad, Romania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.